Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
L. Blanc, F. Grelard, M. Tuck, V. Dartois, A. Peixoto, N. Desbenoit
This paper introduces a multimodal imaging workflow combining MALDI-MSI and IF microscopy to enhance spatial single-cell metabolomics, validated on mouse spleen sections.
bioRxiv · Mar 22, 2024 · PreprintBiochemistry
X. Wang, H. Su, J. B. Wallach, J. C. Wagner, B. J. Braunecker, M. Gardner, K. M. Guinn, T. Klevorn, K. Lin, Y. J. Liu, Y. Liu, D. Mugahid, M. Rodgers, J. Sixsmith, S. Wakabayashi, , D. Schnappinger
This paper develops an engineered Mycobacterium tuberculosis strain with kill switches for a safe TB human challenge model, showing rapid clearance and low escape rates.
bioRxiv · Nov 19, 2023 · PreprintMicrobiology
N. D. Walter, J. P. Ernest, C. Dide-Agossou, A. A. Bauman, M. E. Ramey, K. Rossmassler, L. M. Massoudi, S. Pauly, R. Al Mubarak, M. I. Voskuil, F. Kaya, J. P. Sarathy, M. D. Zimmerman, V. Dartois, B. K. Podell, , G. T. Robertson
The paper shows that Mycobacterium tuberculosis in different lung microenvironments have distinct phenotypes and treatment responses in a mouse model.
bioRxiv · Feb 3, 2023 · PreprintMicrobiology
M. Budak, J. M. Cicchese, P. Maiello, H. J. Borish, A. G. White, H. B. Chishti, J. Tomko, L. J. Frye, D. Fillmore, K. Kracinovsky, J. Sakal, C. A. Scanga, P. L. Lin, V. Dartois, J. J. Linderman, , D. E. Kirschner
This study compares standard TB treatment with moxifloxacin-containing regimens using computational models and experimental validation to identify more effective and patient-friendly treatment options.
bioRxiv · Dec 18, 2022Pharmacology & Toxicology
C. Levine, R. Jadhav, P. Yan, K. Tsotetsi, X. Wang, D. Awasthi, C. Grady, A. Shelke, S. S. Daher, T. Richmann, R. Shrestha, P. Sukheja, J. Patel, P. R. Barnett, R. J. Dikdan, , P. Kumar
This paper develops amidase-dependent pyrazinoic acid prodrugs that bypass PncA activation, showing efficacy against PZA-resistant Mtb.
bioRxiv · Jul 5, 2022 · PreprintMicrobiology
C. G. M. Winchell, B. B. Mishra, J. Y. Phuah, M. Saqib, S. J. Nelson, P. Maiello, C. M. Causgrove, C. L. Ameel, B. Stein, H. J. Borish, A. G. White, E. C. Klein, M. D. Zimmerman, V. Dartois, P. L. Lin, , J. L. Flynn
This study evaluates IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques, finding reduced inflammation and preserved host response without impairing treatment efficacy.
Frontiers in Immunology · May 12, 2020Peer-reviewedMicrobiology
P. Chandra, L. He, M. Zimmerman, G. Yang, S. Koster, M. Ouimet, H. Wang, K. J. Moore, V. Dartois, J. D. Schilling, J. A. Philips
This study shows that blocking fatty acid oxidation in macrophages enhances their ability to control Mycobacterium tuberculosis infection by boosting reactive oxygen species and xenophagy.
bioRxiv · Oct 10, 2019 · PreprintMicrobiology
H. Safi, P. Gopal, S. Lingaraju, S. Ma, C. Levine, V. Dartois, M. Yee, L. Li, L. Blanc, H.-P. H. Liang, S. Husain, M. Hoque, P. Soteropoulos, T. Rustad, D. Sherman, , D. Alland
This paper identifies a novel mechanism of drug tolerance in M. tuberculosis through phase variation in the glpK gene, showing reversible frameshift mutations that contribute to treatment failure and relapse.
bioRxiv · Jul 30, 2019Microbiology